This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Moody's Foresees Junky Valeant Pharmaceuticals Deals

Stocks in this article: VRX ACT

NEW YORK (TheStreet) -- Bond ratings firm Moody's isn't sold on the idea that the four largest generic drug manufacturers Teva Pharmaceuticals (TEVA), Mylan (MYL), Actavis (ACT) and Sandoz can continue to consolidate after years of merger activity in the sector. Moody's also would likely rate a takeover of any of the generics "big four" by serial acquirer Valeant Pharmaceuticals (VRX) as junk.

Will Valeant Overdose on Acquisitions?

Bausch + Lomb Success Less than Meets the Eye

"Mergers between any of the top four generic players would face significant challenges. The high level of fragmentation in the generic pharmaceutical industry and consolidation among its large customers argue for M&A among generic pharmaceutical players. But consolidation between the top four players --Teva Pharmaceutical, Mylan, Actavis plc, and Sandoz (owned by Novartis AG) -- is unlikely given antitrust challenges that would likely require significant divestitures," Moody's lead analyst Jessica Gladstone wrote in a Wednesday note.

The firm does see the prospect that Valeant Pharmaceuticals would go after one of the big four in the generics space, however, it said such a deal would likely be rated below investment grade.

"A hypothetical merger between Valeant and one of the top four generic players could be rated below investment grade. Given Valeant Pharmaceuticals' M&A appetite, we cannot completely rule out that it would buy a generic player," Moody's said.

A merger of a generic drug maker would be outside of Valeant's normal interest in specialty drug makers, Moody's noted. However, the company has recently indicated to the media and in investor presentations that it is bracing for a next big acquisition after buying Medicis and Bausch + Lomb in recent years.

Combining Valeant's existing businesses with a large generic drug manufacturer would give the company size, scale and diversification, however, it would also indicate continued aggressive financial policies that would preclude an investment grade rating, Moody's said.

After making a handful of acquisitions, Valeant Pharmaceuticals promised to pay down its debt and deleverage. Instead, the company has continued to make acquisitions, dramatically increasing its debt stock.

Valeant's long-term debt stood at over $17 billion as of year-end 2013, up nearly three-fold from 2011 year-end levels and nearly five-fold from 2010 levels.

Still, Valeant's acquisitive ways have paid off for shareholders, including ValueAct Capital, which currently holds seats on the company's board of directors.

Valeant shares have risen over 1000% over the past five years, excluding dividends, as the company has divested poorly performing assets and used cheap financing markets to grow by acquisition.

Valeant was trading less than 1% lower in Wednesday trading at $130.66.

-- Written by Antoine Gara in New York

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs